Navigation Links
Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
Date:8/27/2008

CHAPEL-EN-LE-FRITH, England and MILPITAS, California, August 27 /PRNewswire/ -- Peakdale Molecular Ltd (CHAPEL-EN-LE-FRITH, UK) a leading provider in specialist chemistry services to the pharmaceutical and biotechnology industry, and ChemPrintCo LLC (MILPITAS, CA, USA), a unique and cost-effective provider of products and systems for the biotechnology industry, today announce the launch of AssayReady4U(TM).

AssayReady4U(TM) is an online based storefront which allows drug discovery researchers the ability to search, design and select compounds from a live physical collection of screening compounds. Then, using additional options, build their final assay by selecting the exact amount and concentration required to perform their own unique experiments.

The final customer-selected compounds are cleanly and accurately dispensed into SBS standard well plates of the customer's choosing using ChemPrintCo's sophisticated and proprietary hydro-acoustic technologies. Each AssayReady4U plate is sealed in an argon environment and then vacuum-sealed in a moisture barrier bag and placed inside a temperature-controlled pack for shipment. All orders are shipped from stock within 24 hours of completion using a commercial carrier. Upon receipt, the customer adds an appropriate amount of solvent to reach the desired test concentration.

Peakdale's collection is fundamentally rich in novel, GPCR-targeted compounds. All compounds in the collection are selected for their applicability to GPCR research. Well-recognized ligand features are combined with proprietary scaffolds and monomers to produce a set of screening compounds for GPCR hit discovery.

Glenn Killingworth, Director of Business Development at Peakdale said: "I am excited that we have built this collaboration in order to reach the smaller drug-research groups who don't want to build assets to store, handle and plate compounds, but just want to receive ready-to-screen assays from a high quality co
'/>"/>

SOURCE Peakdale Molecular Ltd and ChemPrintCo LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. Molecular sleuths track evolution through the ribosome
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
7. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
8. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
9. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
10. Molecular hula hoop
11. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... NEW YORK , August 27, 2015 ... on enhancing image processing functions in the human vision system, ... Angeles point guard Chris Paul to ... basketball players who want to improve their real-life on-court performance. ... on the court, whether it is shooting a ball or ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... Pharmaceuticals, Inc ., a late-stage epigenetics oncology company, announced today that ... BIO Investor Forum , San Francisco, CA, ... on Target , Panel Discussion: HDACi and Their Progress in the ... Annual Healthcare Conference , New York, NY, November 16, 1:30 PM ...
... Metabolomx, a diagnostic company focused on breath analysis ... was awarded a Small Business Innovation Research (SBIR) contract ... combined Phase I/II Fast-Track contract will support the research ... lung cancer. Metabolomx, proprietary technology is designed ...
... 2011 Amsterdam Molecular Therapeutics (Euronext: AMT), ... today announced that the European Medicines Agency,s (EMA) Committee ... its earlier opinion that Glybera (alipogene tiparvovec) is not ... to the positive recommendation of CHMP Rapporteurs, the Scientific ...
Cached Biology Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 3
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... a disease mechanism that links hereditary amyotrophic lateral sclerosis to ... to a possible therapeutic target. The findings are reported ... Neuroscience . ALS is an adult-onset disease that causes ... five years of diagnosis. Scott Brady, professor and ...
... Long-awaited advances in reducing the cost of certain ... quietly led to production of super-strong forms of the ... story of the current issue of Chemical & ... forms of polyethylene have led to availability of stronger, ...
... of cigarette smoke, tobacco companies have introduced "harm reduction ... But stem cell scientists at the University of California, ... off the tip of a cigarette) from harm reduction ... than sidestream smoke from a conventional brand. ...
Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3Harm reduction cigarettes can be more harmful than conventional brands, researchers report 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Biology Products: